Foundation Medicine, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Operating activities
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense
Stock-based compensation
Provision for doubtful accounts on accounts receivable
Provision for inventory excess and obsolescence
Impairment of fixed assets
Change in fair value of warrant liability
Common stock issued in exchange for professional services
Non-cash interest expense
Amortization of premiums and discounts on marketable securities
Loss on extinguishment of debt
Gain on disposal of long-lived assets
Changes in operating assets and liabilities:
Accounts receivable
Receivable from Roche
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred rent and other non-current liabilities
Deferred revenue
Net cash used in operating activities
Roche related-party deferred revenue

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Increase in restricted cash
Net cash used in investing activities
Purchases of marketable securities and other investments
Proceeds from maturities of marketable securities
Change in restricted cash
Net cash provided by (used in) investing activities

Financing activities
Proceeds from issuance of common stock, net of issuance costs
Roche
Total proceeds from issuance of common stock, net of issuance costs

Proceeds from issuance of Preferred Stock and related investor rights, net of issuance costs
Proceeds from issuance of Series B Preferred Stock, net of issuance costs
Proceeds from indebtedness to Roche
Proceeds from issuance of restricted stock and stock option exercises
Payment of debt issuance costs
Payments of notes payable
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Supplemental disclosure of non-cash investing and financing activities
Conversion of convertible preferred stock into common stock
Acquisition of property and equipment included in accounts payable and accrued expenses
Reclassification of warrant liability to additional paid-in capital
Accretion of convertible preferred stock to redemption value

Comments